Wang Jiping, Hassett James M, Dayton Merril T, Kulaylat Mahmoud N
Department of Surgery, University at Buffalo, State University of New York, Buffalo, New York, USA.
Ann Surg Oncol. 2008 Jun;15(6):1600-8. doi: 10.1245/s10434-007-9716-x. Epub 2008 Mar 8.
BACKGROUND: Recent literature has shown that lymph node ratio (LNR) is superior to the number of positive lymph nodes (pLNs) in predicting the prognosis in several malignances other than colon cancer. We hypothesize that LNR may play a similar role in stage III colon cancer. METHODS: We included 24,477 stage III colon cancer cases from the Surveillance, Epidemiology, and End Results cancer registry. Patients were categorized into four groups, LNR1 to 4, according to cutoff points 1/14, 0.25, and 0.50. Kaplan-Meier and Cox proportional hazard model were used to evaluate the prognostic effect and estimate the relative risk (RR) and 95% confidence interval (CI) of LNR. RESULTS: The 5-year survival for patients with stage IIIA, IIIB, and IIIC was 71.3%, 51.7%, and 34.0%, respectively (P < .0001). There was no survival difference among LNR1 to LNR4 for stage IIIA patients. In stage IIIB patients, the 5-year survival for those with LNR1 to LNR4 was 63.5%, 54.7%, 44.4%, and 34.2%, respectively (P < .0001). In stage IIIC patients, the 5-year survival for those with LNR2 to LNR4 was 49.6%, 41.7%, and 25.2%, respectively (P < .0001). LNR is an independent predictor of survival after adjusting patient's age, tumor size, tumor grade, race, number of pLNs, and total number of LNs harvested. (RR 2.30, 95% CI 2.08-2.55). CONCLUSION: Patients with stage IIIB and IIIC colon cancer represent a heterogeneous group of patients with the majority either overstaged or understaged. LNR is a more accurate prognostic method for stage III colon cancer patients. We propose an algorithm to incorporate LNR into current AJCC staging system.
背景:近期文献表明,在预测除结肠癌之外的几种恶性肿瘤的预后方面,淋巴结比率(LNR)优于阳性淋巴结(pLNs)数量。我们假设LNR在III期结肠癌中可能发挥类似作用。 方法:我们纳入了监测、流行病学和最终结果癌症登记处的24477例III期结肠癌病例。根据截断点1/14、0.25和0.50将患者分为四组,即LNR1至LNR4。采用Kaplan-Meier法和Cox比例风险模型评估LNR的预后效果,并估计其相对风险(RR)和95%置信区间(CI)。 结果:IIIA期、IIIB期和IIIC期患者的5年生存率分别为71.3%、51.7%和34.0%(P <.0001)。IIIA期患者的LNR1至LNR4之间无生存差异。在IIIB期患者中,LNR1至LNR4患者的5年生存率分别为63.5%、54.7%、44.4%和34.2%(P <.0001)。在IIIC期患者中,LNR2至LNR4患者的5年生存率分别为49.6%、41.7%和25.2%(P <.0001)。在调整患者年龄、肿瘤大小、肿瘤分级、种族、pLNs数量和采集的淋巴结总数后,LNR是生存的独立预测因素(RR 2.30,95% CI 2.08 - 2.55)。 结论:IIIB期和IIIC期结肠癌患者是一组异质性患者,大多数患者分期过高或过低。LNR是III期结肠癌患者更准确的预后评估方法。我们提出一种将LNR纳入当前美国癌症联合委员会(AJCC)分期系统的算法。
Ann Surg Oncol. 2008-6
Ann Surg Oncol. 2007-5
Int J Radiat Oncol Biol Phys. 2009-7-1
Am J Surg. 2007-12
J Surg Oncol. 2009-9-1
J Am Coll Surg. 2008-2
Eur J Surg Oncol. 2008-7
Ann Surg Oncol. 2024-3